Loading…
Antibody incidence and red blood cell transfusions in patients on daratumumab
Background Daratumumab (Dara), an anti‐CD38 monoclonal antibody for hematologic malignancies, interferes with routine blood bank testing, specifically affecting the antibody screen and identification panels. In 2016, the AABB recommended performing a baseline phenotype or genotype before a patient (...
Saved in:
| Published in: | Transfusion (Philadelphia, Pa.) Pa.), 2021-12, Vol.61 (12), p.3468-3472 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3937-531d062d5da777eeb633a48223ce36543f792546a8e140f4bc73508aa564516d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3937-531d062d5da777eeb633a48223ce36543f792546a8e140f4bc73508aa564516d3 |
| container_end_page | 3472 |
| container_issue | 12 |
| container_start_page | 3468 |
| container_title | Transfusion (Philadelphia, Pa.) |
| container_volume | 61 |
| creator | Tauscher, Craig Moldenhauer, Sheila Bryant, Sandra DiGuardo, Margaret Jacob, Eapen K. |
| description | Background
Daratumumab (Dara), an anti‐CD38 monoclonal antibody for hematologic malignancies, interferes with routine blood bank testing, specifically affecting the antibody screen and identification panels. In 2016, the AABB recommended performing a baseline phenotype or genotype before a patient (Pt) begins taking anti‐CD38 to avoid this interference and potential problems with transfusion. The objective of this study was to assess red blood cell (RBC) utilization and subsequent incidence of alloimmunization to the transfused RBCs in patients receiving Dara.
Methods and Materials
We monitored 244 patients taking Dara to determine their red blood cell transfusions and incidence of clinically significant antibody formation before and following administration of Dara. Poisson generalized estimating equations with log link were used comparing the post‐Dara incidence and prevalence to those prior, with significance defined as p |
| doi_str_mv | 10.1111/trf.16687 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2607500897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2607500897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3937-531d062d5da777eeb633a48223ce36543f792546a8e140f4bc73508aa564516d3</originalsourceid><addsrcrecordid>eNp1kE1LwzAYgIMobk4P_gEJePLQLd9pj2NsKkwEmeeQNil0tMlMWmT_3minN8MLuTw878sDwC1Gc5zeog_1HAuRyzMwxZzKjBQFPwdThBjOMKZkAq5i3COESIHwJZhQJrBMMwUvS9c3pTdH2LiqMdZVFmpnYLAGlq33Bla2bWEftIv1EBvvYiLhQfeNdX2E3kGjg-6Hbuh0eQ0uat1Ge3P6Z-B9s96tnrLt6-PzarnNKlqk8zjFBgliuNFSSmtLQalmOSG0slRwRmtZEM6Ezi1mqGZlJSlHudZcMI6FoTNwP3oPwX8MNvZq74fg0kpFBJIcobyQiXoYqSr4GIOt1SE0nQ5HhZH6DqdSOPUTLrF3J-NQdtb8kb-lErAYgc-mtcf_TWr3thmVX5_Odkw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2607500897</pqid></control><display><type>article</type><title>Antibody incidence and red blood cell transfusions in patients on daratumumab</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Tauscher, Craig ; Moldenhauer, Sheila ; Bryant, Sandra ; DiGuardo, Margaret ; Jacob, Eapen K.</creator><creatorcontrib>Tauscher, Craig ; Moldenhauer, Sheila ; Bryant, Sandra ; DiGuardo, Margaret ; Jacob, Eapen K.</creatorcontrib><description>Background
Daratumumab (Dara), an anti‐CD38 monoclonal antibody for hematologic malignancies, interferes with routine blood bank testing, specifically affecting the antibody screen and identification panels. In 2016, the AABB recommended performing a baseline phenotype or genotype before a patient (Pt) begins taking anti‐CD38 to avoid this interference and potential problems with transfusion. The objective of this study was to assess red blood cell (RBC) utilization and subsequent incidence of alloimmunization to the transfused RBCs in patients receiving Dara.
Methods and Materials
We monitored 244 patients taking Dara to determine their red blood cell transfusions and incidence of clinically significant antibody formation before and following administration of Dara. Poisson generalized estimating equations with log link were used comparing the post‐Dara incidence and prevalence to those prior, with significance defined as p < .05.
Results
From September 1, 2015 to December 22, 2018, 244 patients on Dara were identified, of which 145 patients (59.4%) received a red blood cell transfusion. Antibody screens were performed on 97 of the 145 patients at least 2 weeks following RBC transfusion. Four of the total transfused patients (2.8% total, 4.1% patients with follow‐up antibody screen testing) formed new clinically significant alloantibodies, which was not significantly different from Asare's hematologic incidence (p = .98/p = .49).
Conclusions
This study showed our patients on Dara did not form alloantibodies following RBC transfusion at a higher incidence than similar patient populations.
See editorial on page 3283–3285, in this issue</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/trf.16687</identifier><identifier>PMID: 34617617</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Alloantibodies ; Antibodies ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Blood ; Blood transfusion ; CD38 antigen ; daratumamab ; Erythrocyte Transfusion - adverse effects ; Erythrocytes ; Genotypes ; Humans ; Immunohematology ; Immunotherapy ; Incidence ; Isoantibodies ; Isoimmunization ; Monoclonal antibodies ; monoclonal antibody interference ; Multiple Myeloma ; Patients ; Phenotypes ; RBC alloimmunization ; red blood cell transfusion ; Targeted cancer therapy ; Transfusion</subject><ispartof>Transfusion (Philadelphia, Pa.), 2021-12, Vol.61 (12), p.3468-3472</ispartof><rights>2021 AABB.</rights><rights>2021 AABB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3937-531d062d5da777eeb633a48223ce36543f792546a8e140f4bc73508aa564516d3</citedby><cites>FETCH-LOGICAL-c3937-531d062d5da777eeb633a48223ce36543f792546a8e140f4bc73508aa564516d3</cites><orcidid>0000-0003-2692-6613</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34617617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tauscher, Craig</creatorcontrib><creatorcontrib>Moldenhauer, Sheila</creatorcontrib><creatorcontrib>Bryant, Sandra</creatorcontrib><creatorcontrib>DiGuardo, Margaret</creatorcontrib><creatorcontrib>Jacob, Eapen K.</creatorcontrib><title>Antibody incidence and red blood cell transfusions in patients on daratumumab</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>Background
Daratumumab (Dara), an anti‐CD38 monoclonal antibody for hematologic malignancies, interferes with routine blood bank testing, specifically affecting the antibody screen and identification panels. In 2016, the AABB recommended performing a baseline phenotype or genotype before a patient (Pt) begins taking anti‐CD38 to avoid this interference and potential problems with transfusion. The objective of this study was to assess red blood cell (RBC) utilization and subsequent incidence of alloimmunization to the transfused RBCs in patients receiving Dara.
Methods and Materials
We monitored 244 patients taking Dara to determine their red blood cell transfusions and incidence of clinically significant antibody formation before and following administration of Dara. Poisson generalized estimating equations with log link were used comparing the post‐Dara incidence and prevalence to those prior, with significance defined as p < .05.
Results
From September 1, 2015 to December 22, 2018, 244 patients on Dara were identified, of which 145 patients (59.4%) received a red blood cell transfusion. Antibody screens were performed on 97 of the 145 patients at least 2 weeks following RBC transfusion. Four of the total transfused patients (2.8% total, 4.1% patients with follow‐up antibody screen testing) formed new clinically significant alloantibodies, which was not significantly different from Asare's hematologic incidence (p = .98/p = .49).
Conclusions
This study showed our patients on Dara did not form alloantibodies following RBC transfusion at a higher incidence than similar patient populations.
See editorial on page 3283–3285, in this issue</description><subject>Alloantibodies</subject><subject>Antibodies</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Blood</subject><subject>Blood transfusion</subject><subject>CD38 antigen</subject><subject>daratumamab</subject><subject>Erythrocyte Transfusion - adverse effects</subject><subject>Erythrocytes</subject><subject>Genotypes</subject><subject>Humans</subject><subject>Immunohematology</subject><subject>Immunotherapy</subject><subject>Incidence</subject><subject>Isoantibodies</subject><subject>Isoimmunization</subject><subject>Monoclonal antibodies</subject><subject>monoclonal antibody interference</subject><subject>Multiple Myeloma</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>RBC alloimmunization</subject><subject>red blood cell transfusion</subject><subject>Targeted cancer therapy</subject><subject>Transfusion</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LwzAYgIMobk4P_gEJePLQLd9pj2NsKkwEmeeQNil0tMlMWmT_3minN8MLuTw878sDwC1Gc5zeog_1HAuRyzMwxZzKjBQFPwdThBjOMKZkAq5i3COESIHwJZhQJrBMMwUvS9c3pTdH2LiqMdZVFmpnYLAGlq33Bla2bWEftIv1EBvvYiLhQfeNdX2E3kGjg-6Hbuh0eQ0uat1Ge3P6Z-B9s96tnrLt6-PzarnNKlqk8zjFBgliuNFSSmtLQalmOSG0slRwRmtZEM6Ezi1mqGZlJSlHudZcMI6FoTNwP3oPwX8MNvZq74fg0kpFBJIcobyQiXoYqSr4GIOt1SE0nQ5HhZH6DqdSOPUTLrF3J-NQdtb8kb-lErAYgc-mtcf_TWr3thmVX5_Odkw</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Tauscher, Craig</creator><creator>Moldenhauer, Sheila</creator><creator>Bryant, Sandra</creator><creator>DiGuardo, Margaret</creator><creator>Jacob, Eapen K.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0003-2692-6613</orcidid></search><sort><creationdate>202112</creationdate><title>Antibody incidence and red blood cell transfusions in patients on daratumumab</title><author>Tauscher, Craig ; Moldenhauer, Sheila ; Bryant, Sandra ; DiGuardo, Margaret ; Jacob, Eapen K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3937-531d062d5da777eeb633a48223ce36543f792546a8e140f4bc73508aa564516d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alloantibodies</topic><topic>Antibodies</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Blood</topic><topic>Blood transfusion</topic><topic>CD38 antigen</topic><topic>daratumamab</topic><topic>Erythrocyte Transfusion - adverse effects</topic><topic>Erythrocytes</topic><topic>Genotypes</topic><topic>Humans</topic><topic>Immunohematology</topic><topic>Immunotherapy</topic><topic>Incidence</topic><topic>Isoantibodies</topic><topic>Isoimmunization</topic><topic>Monoclonal antibodies</topic><topic>monoclonal antibody interference</topic><topic>Multiple Myeloma</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>RBC alloimmunization</topic><topic>red blood cell transfusion</topic><topic>Targeted cancer therapy</topic><topic>Transfusion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tauscher, Craig</creatorcontrib><creatorcontrib>Moldenhauer, Sheila</creatorcontrib><creatorcontrib>Bryant, Sandra</creatorcontrib><creatorcontrib>DiGuardo, Margaret</creatorcontrib><creatorcontrib>Jacob, Eapen K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tauscher, Craig</au><au>Moldenhauer, Sheila</au><au>Bryant, Sandra</au><au>DiGuardo, Margaret</au><au>Jacob, Eapen K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody incidence and red blood cell transfusions in patients on daratumumab</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2021-12</date><risdate>2021</risdate><volume>61</volume><issue>12</issue><spage>3468</spage><epage>3472</epage><pages>3468-3472</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><abstract>Background
Daratumumab (Dara), an anti‐CD38 monoclonal antibody for hematologic malignancies, interferes with routine blood bank testing, specifically affecting the antibody screen and identification panels. In 2016, the AABB recommended performing a baseline phenotype or genotype before a patient (Pt) begins taking anti‐CD38 to avoid this interference and potential problems with transfusion. The objective of this study was to assess red blood cell (RBC) utilization and subsequent incidence of alloimmunization to the transfused RBCs in patients receiving Dara.
Methods and Materials
We monitored 244 patients taking Dara to determine their red blood cell transfusions and incidence of clinically significant antibody formation before and following administration of Dara. Poisson generalized estimating equations with log link were used comparing the post‐Dara incidence and prevalence to those prior, with significance defined as p < .05.
Results
From September 1, 2015 to December 22, 2018, 244 patients on Dara were identified, of which 145 patients (59.4%) received a red blood cell transfusion. Antibody screens were performed on 97 of the 145 patients at least 2 weeks following RBC transfusion. Four of the total transfused patients (2.8% total, 4.1% patients with follow‐up antibody screen testing) formed new clinically significant alloantibodies, which was not significantly different from Asare's hematologic incidence (p = .98/p = .49).
Conclusions
This study showed our patients on Dara did not form alloantibodies following RBC transfusion at a higher incidence than similar patient populations.
See editorial on page 3283–3285, in this issue</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>34617617</pmid><doi>10.1111/trf.16687</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-2692-6613</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1132 |
| ispartof | Transfusion (Philadelphia, Pa.), 2021-12, Vol.61 (12), p.3468-3472 |
| issn | 0041-1132 1537-2995 |
| language | eng |
| recordid | cdi_proquest_journals_2607500897 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Alloantibodies Antibodies Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Blood Blood transfusion CD38 antigen daratumamab Erythrocyte Transfusion - adverse effects Erythrocytes Genotypes Humans Immunohematology Immunotherapy Incidence Isoantibodies Isoimmunization Monoclonal antibodies monoclonal antibody interference Multiple Myeloma Patients Phenotypes RBC alloimmunization red blood cell transfusion Targeted cancer therapy Transfusion |
| title | Antibody incidence and red blood cell transfusions in patients on daratumumab |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A12%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20incidence%20and%20red%20blood%20cell%20transfusions%20in%20patients%20on%20daratumumab&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Tauscher,%20Craig&rft.date=2021-12&rft.volume=61&rft.issue=12&rft.spage=3468&rft.epage=3472&rft.pages=3468-3472&rft.issn=0041-1132&rft.eissn=1537-2995&rft_id=info:doi/10.1111/trf.16687&rft_dat=%3Cproquest_cross%3E2607500897%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3937-531d062d5da777eeb633a48223ce36543f792546a8e140f4bc73508aa564516d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2607500897&rft_id=info:pmid/34617617&rfr_iscdi=true |